Adjuvant Therapy After Margin-Positive Distal Pancreatectomy for Solid Pseudopapillary Neoplasm
For margin-positive (R1) resection of solid pseudopapillary neoplasm (SPN), observation with close surveillance is the recommended approach, as adjuvant chemotherapy or radiation has not been proven beneficial for this specific tumor type and complete surgical resection—even with positive margins—typically results in excellent long-term outcomes.
Key Clinical Context
Solid pseudopapillary neoplasm is fundamentally different from pancreatic adenocarcinoma, and the extensive adjuvant therapy guidelines provided in the evidence 1 apply specifically to pancreatic ductal adenocarcinoma, not to SPN. This distinction is critical for clinical decision-making.
Evidence-Based Rationale
Why Observation is Appropriate
Excellent prognosis despite positive margins: Multiple case series demonstrate that SPN patients with R1 resections have favorable outcomes without adjuvant therapy 2, 3, 4, 5
Low malignant potential: SPN is a low-grade malignant tumor with inherently indolent behavior, even when incompletely resected 2, 6
Lack of evidence for adjuvant benefit: No studies demonstrate survival improvement with chemotherapy or radiation for SPN 2, 3, 4
Pediatric data supports observation: A recent pediatric series showed that despite positive margins in 9 of 16 patients, only 2 experienced local recurrence, and all patients remained alive without adjuvant therapy 5
When to Consider Intervention
Re-resection should be considered if:
- Positive margins are technically amenable to further resection
- The patient has good performance status
- Complete (R0) resection appears achievable
Systemic therapy may be considered only in exceptional circumstances:
- Documented metastatic disease (extremely rare) 7
- Unresectable recurrent disease
- Rapidly progressive disease despite surgical intervention
However, even in metastatic cases, there is no established standard chemotherapy regimen, and outcomes remain poor 7.
Surveillance Strategy
Implement intensive long-term surveillance:
- Imaging frequency: CT or MRI every 3-6 months for the first 2 years, then every 6-12 months for at least 5 years 2, 3, 6
- Duration: Lifelong surveillance is warranted given the potential for late recurrences (even decades later)
- Rationale: Late recurrences can occur, but when detected early, surgical re-resection often remains curative 2, 3
Critical Pitfalls to Avoid
Do not extrapolate pancreatic adenocarcinoma guidelines to SPN: The ASCO and NCCN guidelines for adjuvant therapy after R1 resection 1 recommend chemotherapy ± chemoradiation for adenocarcinoma, but these recommendations are disease-specific and should not be applied to SPN
Do not delay surveillance: The primary risk with R1 resection is local recurrence, which is best managed with early detection and surgical re-intervention rather than empiric adjuvant therapy
Do not assume all pancreatic tumors behave similarly: SPN has distinct biology, predominantly affects young women, and has dramatically better prognosis than adenocarcinoma 2, 3, 6
Special Considerations
Molecular testing: CTNNB1 mutations are characteristic of SPN and can confirm diagnosis, but do not currently guide therapy decisions 7
Multidisciplinary review: While observation is standard, discussion at a high-volume center with SPN experience is reasonable for complex cases 3, 6
Patient counseling: Emphasize the excellent overall prognosis (>95% long-term survival) while stressing the importance of lifelong surveillance 2, 4, 5